Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Queensland Health
Medtronic
Healthtrust
AstraZeneca
Farmers Insurance
Express Scripts
Moodys
Citi
US Army

Generated: August 23, 2017

DrugPatentWatch Database Preview

Rhodes Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for RHODES PHARMS, and when can generic versions of RHODES PHARMS drugs launch?

RHODES PHARMS has fifteen approved drugs.

There are seven US patents protecting RHODES PHARMS drugs and there have been four Paragraph IV challenges on RHODES PHARMS drugs in the past three years.

There are forty-three patent family members on RHODES PHARMS drugs in fifteen countries.

Summary for Applicant: Rhodes Pharms

Patents:7
Tradenames:10
Ingredients:9
NDAs:15
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rhodes Pharms
BUPRENORPHINE HYDROCHLORIDE
buprenorphine hydrochloride
TABLET;SUBLINGUAL207276-001Mar 27, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Rhodes Pharms
OXYCODONE HYDROCHLORIDE
oxycodone hydrochloride
TABLET;ORAL091490-005Mar 9, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe
Rhodes Pharms
APTENSIO XR
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL205831-007Apr 17, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Rhodes Pharms
APTENSIO XR
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL205831-007Apr 17, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Rhodes Pharms
MORPHINE SULFATE
morphine sulfate
TABLET, EXTENDED RELEASE;ORAL074862-003Jul 7, 1998ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for RHODES PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
methylphenidate hydrochloride
Extended-release Capsules30 mg
APTENSIO XR
3/28/2016
methylphenidate hydrochloride
Extended-release Capsules15 mg, 20 mg, 40 mg and 50 mg
APTENSIO XR
12/28/2015
methylphenidate hydrochloride
Extended-release Capsules10 mg
APTENSIO XR
12/24/2015
methylphenidate hydrochloride
Extended-release Capsules60 mg
APTENSIO XR
12/23/2015
hydromorphone hydrochloride
Tablets2 mg, 4 mg, and 8 mg
DILAUDID
8/5/2013
hydromorphone hydrochloride
Injection2 mg/mL
DILAUDID
6/22/2011
hydromorphone hydrochloride
Oral Solution5 mg/5mL
DILAUDID
2/25/2011

Non-Orange Book Patents for Rhodes Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,512,117 Hydromorphone and hydrocodone compositions and methods for their synthesis► Subscribe
6,673,367 Controlled/modified release oral methylphenidate formulations► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Rhodes Pharms Drugs

Country Document Number Estimated Expiration
Lithuania1967191► Subscribe
Denmark1967191► Subscribe
Japan2012184235► Subscribe
European Patent Office2338891► Subscribe
Portugal1967191► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Rhodes Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
292Luxembourg► SubscribePRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Harvard Business School
Baxter
Boehringer Ingelheim
UBS
Covington
McKinsey
McKesson
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot